Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Myriad Genetics, Inc. before investing.

In this article, we go over a few key elements for understanding Myriad Genetics, Inc.’s stock price such as:

• Myriad Genetics, Inc.’s current stock price and volume
• Why Myriad Genetics, Inc.’s stock price changed recently
• Upgrades and downgrades for MYGN from analysts
• MYGN’s stock price momentum as measured by its relative strength

About Myriad Genetics, Inc. (MYGN)

Before we jump into Myriad Genetics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Want to learn more about Myriad Genetics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Myriad Genetics, Inc..

Myriad Genetics, Inc.’s Stock Price as of Market Close

As of September 04, 2024, 4:00 PM, CST, Myriad Genetics, Inc.’s stock price was $25.36.

Myriad Genetics, Inc. is down 7.65% from its previous closing price of $27.46.

During the last market session, Myriad Genetics, Inc.’s stock traded between $27.37 and $28.51. Currently, there are 90.60 million shares of Myriad Genetics, Inc. stock available for purchase.

Unfortunately, Myriad Genetics, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Myriad Genetics, Inc. Stock Price History

Myriad Genetics, Inc.’s (MYGN) price is currently down 10.48% so far this month.

During the month of September, Myriad Genetics, Inc.’s stock price has reached a high of $28.51 and a low of $24.74.

Over the last year, Myriad Genetics, Inc. has hit prices as high as $29.08 and as low as $13.82. Year to date, Myriad Genetics, Inc.’s stock is up 74.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Myriad Genetics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 03, 2024, there were 2 analysts who downgraded Myriad Genetics, Inc.’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Myriad Genetics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Myriad Genetics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Myriad Genetics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Myriad Genetics, Inc. (MYGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Myriad Genetics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 03, 2024, Myriad Genetics, Inc. has a weighted four-quarter relative price strength of 8.23%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Myriad Genetics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Myriad Genetics, Inc. Stock Price: Bottom Line

As of September 4, 2024, Myriad Genetics, Inc.’s stock price is $25.36, which is down 7.65% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Myriad Genetics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.